Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies

By /

Forbion participated in the November 2025 series B round of Gate Bioscience, which earlier this week inked an up to $870 million deal extension with Eli Lilly.

Scroll to Top